Veracyte (VCYT) Tops Q3 EPS by 13c, Revenues Beat; Boosts FY18 Revenue Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Veracyte Announces Third Quarter 2018 Financial Results
October 29, 2018 4:05 PM EDTRevenue Grew 34 Percent and Genomic Test Volume Increased 23 Percent
Company Increases Annual Revenue Guidance and Lowers Cash Burn Guidance for 2018
Conference Call and Webcast Today at 4:30 p.m. EDT
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Veracyte, Inc. (Nasdaq: VCYT) today announced financial results for the third quarter ended September 30, 2018 and provided an update on recent business progress. For the third quarter of 2018, revenue was $23.5 million, an increase of 34 percent, compared with $17.5 million for the third quarter of 2017. Genomic test volume was 8,006, an... More
